sur Theranexus (EPA:ALTHX)
Theranexus Strengthens its Treasury and Develops its Partnerships
On January 30, 2025, Theranexus announced a cash position of €1.0 million as of December 31, 2024, a decrease from €1.9 million as of September 30, 2024. However, this situation has evolved favorably, with cash reaching €4.0 million as of January 29, 2025. This strengthening is due to a key partnership with Exeltis, which provided an initial payment of €2 million, and to financing from Bpifrance of €1.1 million for the NeuroLead and PickASO projects.
Theranexus, a specialist in rare neurological diseases, is leveraging its partnership with Insud Pharma to market TX01 for Niemann-Pick C and Gaucher diseases. A restructuring of its debt has been agreed with banking partners, including a deferral of repayments. The company is also aiming to launch the pivotal study of its Batten-1 candidate in 2025.
R. P.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Theranexus